Imaging PARP with [(18)F]rucaparib in pancreatic cancer models

PURPOSE: Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. However, not all patients receive the same benefit from rucaparib-maintenance thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Chung Ying, Chen, Zijun, Destro, Gianluca, Veal, Mathew, Lau, Doreen, O’Neill, Edward, Dias, Gemma, Mosley, Michael, Kersemans, Veerle, Guibbal, Florian, Gouverneur, Véronique, Cornelissen, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399069/
https://www.ncbi.nlm.nih.gov/pubmed/35614267
http://dx.doi.org/10.1007/s00259-022-05835-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399069/
https://www.ncbi.nlm.nih.gov/pubmed/35614267
http://dx.doi.org/10.1007/s00259-022-05835-4

Ejemplares similares